ECSP10010695A - Compuestos de piridina - Google Patents

Compuestos de piridina

Info

Publication number
ECSP10010695A
ECSP10010695A EC2010010695A ECSP10010695A ECSP10010695A EC SP10010695 A ECSP10010695 A EC SP10010695A EC 2010010695 A EC2010010695 A EC 2010010695A EC SP10010695 A ECSP10010695 A EC SP10010695A EC SP10010695 A ECSP10010695 A EC SP10010695A
Authority
EC
Ecuador
Prior art keywords
compounds
medicaments
piridine
piridine compounds
humans
Prior art date
Application number
EC2010010695A
Other languages
English (en)
Inventor
Kevin Michael Foote
Bernard Christophe Barlaam
Clifford David Jones
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP10010695A publication Critical patent/ECSP10010695A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos que inhiben la función de la quinasa de adhesión focal, con los procesos para prepararlos, las composiciones farmacéuticas que los contienen como ingrediente activo, su uso como medicamentos y su uso en la fabricación de medicamentos para tratar enfermedades como el cáncer en animales de sangre caliente como el ser humano.
EC2010010695A 2008-06-17 2010-12-17 Compuestos de piridina ECSP10010695A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17

Publications (1)

Publication Number Publication Date
ECSP10010695A true ECSP10010695A (es) 2011-01-31

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010695A ECSP10010695A (es) 2008-06-17 2010-12-17 Compuestos de piridina

Country Status (18)

Country Link
US (1) US8569298B2 (es)
EP (1) EP2303861B1 (es)
JP (1) JP5551689B2 (es)
KR (1) KR101695501B1 (es)
CN (1) CN102124000B (es)
AU (1) AU2009261764B2 (es)
BR (1) BRPI0914927B8 (es)
CA (1) CA2726508C (es)
CR (1) CR11854A (es)
DO (1) DOP2010000390A (es)
EA (1) EA020807B1 (es)
EC (1) ECSP10010695A (es)
ES (1) ES2472323T3 (es)
HK (1) HK1155170A1 (es)
IL (1) IL209727A0 (es)
MX (1) MX2010014057A (es)
WO (1) WO2009153589A1 (es)
ZA (1) ZA201100388B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
ES2642586T3 (es) 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
AU2011276552B2 (en) 2010-06-29 2015-09-03 Verastem, Inc. Oral formulation of kinase inhibitors
EP2588476A4 (en) * 2010-06-30 2014-07-23 Verastem Inc SYNTHESIS AND USE OF KINASE INHIBITORS
EA026385B9 (ru) 2010-07-02 2017-08-31 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EA201391076A1 (ru) * 2011-01-26 2014-07-30 Глэксосмитклайн Интеллекчуал Проперти Лимитед Комбинации
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
DK2675793T3 (en) 2011-02-17 2018-11-12 Cancer Therapeutics Crc Pty Ltd FAK INHIBITORS
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
EP3275870B1 (en) 2011-05-10 2020-02-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
AU2013205240B2 (en) 2012-03-16 2016-02-11 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
TN2016000529A1 (en) * 2014-06-17 2018-04-04 Pfizer Substituted dihydroisoquinolinone compounds
US9442005B2 (en) * 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
NZ733950A (en) 2014-12-23 2018-08-31 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
EP3313404A4 (en) 2015-06-29 2019-08-07 Verastem, Inc. THERAPEUTIC COMPOSITIONS, ASSOCIATIONS AND METHODS OF USE
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
WO2019166558A1 (en) 2018-02-28 2019-09-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
EP3759097A1 (en) 2018-02-28 2021-01-06 Basf Se Use of n-functionalized alkoxy pyrazole compounds as nitrification inhibitors
SG11202008696RA (en) 2018-03-12 2020-10-29 Inst Nat Sante Rech Med Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
AU2020365108A1 (en) * 2019-10-18 2022-04-21 Atengen, Inc. 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
CA3219128A1 (en) 2021-05-21 2022-11-24 Barbara Nave Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (de) 2003-08-07 2005-02-24 Bayer Materialscience Ag Neue Katalysatoren für die selektive Isocyanatdimerisierung
PL2287156T3 (pl) * 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
CA2571482A1 (en) 2004-06-21 2005-12-29 Pharmacia & Upjohn Company Llc Pyk2 inhibitors for stimulation of osteoblast function
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP1966192B1 (en) * 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
AU2006327871A1 (en) 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CN103641816A (zh) 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2008115369A2 (en) 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase
JP2010533729A (ja) * 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン

Also Published As

Publication number Publication date
BRPI0914927B8 (pt) 2021-05-25
ZA201100388B (en) 2011-10-26
BRPI0914927A2 (pt) 2017-06-20
CA2726508C (en) 2016-06-07
CN102124000A (zh) 2011-07-13
IL209727A0 (en) 2011-02-28
DOP2010000390A (es) 2011-01-15
ES2472323T3 (es) 2014-06-30
JP5551689B2 (ja) 2014-07-16
EP2303861B1 (en) 2014-04-23
JP2011524411A (ja) 2011-09-01
BRPI0914927B1 (pt) 2020-10-06
MX2010014057A (es) 2011-03-21
WO2009153589A1 (en) 2009-12-23
US8569298B2 (en) 2013-10-29
US20110166139A1 (en) 2011-07-07
AU2009261764A1 (en) 2009-12-23
EP2303861A1 (en) 2011-04-06
AU2009261764B2 (en) 2013-01-10
EA020807B1 (ru) 2015-01-30
KR20110023884A (ko) 2011-03-08
CN102124000B (zh) 2014-09-17
CR11854A (es) 2011-02-25
CA2726508A1 (en) 2009-12-23
HK1155170A1 (en) 2012-05-11
EA201100032A1 (ru) 2012-01-30
KR101695501B1 (ko) 2017-01-11

Similar Documents

Publication Publication Date Title
CR11854A (es) Compuestos de piridina
CO6721010A2 (es) Antagonistas de mdm2 de espiro-oxindol
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
UY30282A1 (es) Compuestos quimicos
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
CO6640285A2 (es) 5-alquinil-pirimidinas
UY32383A (es) Dionas cíclicas herbicidamente activas, derivados, procesos para su preparación composiciones que las comprenden y usos de las mismas
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
DOP2015000170A (es) Compuestos químicos
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
UY31141A1 (es) Compuestos de piperidina y sus usos
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY30880A1 (es) 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor